New drug combo trial targets Tough-to-Treat liver cancer
Disease control
Not yet recruiting
This study is testing a combination of two immunotherapy drugs (tremelimumab and durvalumab) with two chemotherapy drugs (gemcitabine and cisplatin) for people with an advanced, hard-to-treat form of liver cancer called combined hepatocellular-cholangiocarcinoma (cHCC-CCA). The g…
Phase: PHASE2 • Sponsor: Mehmet Akce • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC